The US Food and Drug Administration has approved a new treatment for HIV-1 infection developed by ViiV Healthcare. Tivicay (dolutegravir) is an integrase strand transfer inhibitor to be used in combination with other antiretroviral drugs.
Scientists in the Netherlands have reported that the DNA in the nucleus of an embryonic stem cell appears to be folded in such a way that all stem cell genes are located near one another. This ensures that stem cells don’t change into other cell types.
Analysing data from a small population in northeastern Finland, an international research group has identified a genetic link to schizophrenia, as well as an association with the rare disease Fragile X syndrome. The findings were reported in Nature Neuroscience.
Researchers from Ireland have reported that the probiotic B. infantis 35624 relieved symptoms in three inflammatory disorders underscoring the role that the gut microbiota plays in human health. The study appears in the July/August issue of Gut Microbes.
Addex Therapeutics Ltd has raised gross proceeds of CHF 3.2 million ($3.5 million) in a private placement of shares enabling it continue operations beyond its next important clinical event – the reporting of data from a study in anxious depression.
Novo Nordisk A/S said it expects to start a cardiovascular outcomes trial for the diabetes drug Tresiba (insulin degludec) late this year in order to satisfy requirements by the US Food and Drug Administration which turned down the drug in February.
GlaxoSmithKline Plc has launched a new $50 million venture capital fund in Cambridge, Massachusetts, US that will invest in companies working in the field of bioelectronic medicine. The term ‘bioelectronic medicine’ refers to non-pharmaceutical interventions that seek to treat disease by changing or directing electrical signals in the body.
H. Lundbeck A/S has raised its guidance for revenue and earnings this year on the back of strong growth of new products in the first half year. A one-off fine from the European Commission however contributed to a loss for the second quarter.
A Phase 3 study of Afinitor (everolimus) in patients with metastatic liver cancer did not meet its primary endpoint of overall survival, Novartis announced on 7 August. The Swiss multinational said it won’t seek to register the drug for this indication.
Cytos Biotechnology Ltd of Switzerland said that top-line data from a Phase 2b clinical study of its lead product for allergic asthma should be available during the second quarter of 2014. The trial is taking place in eight countries.